Importance of assessing renal function in patients treated with Pradaxa® (dabigatran etexilate)

Boehringer Ingelheim would like to inform healthcare professionals of new recommendations to assess renal function in patients being treated with or being considered for treatment with Pradaxa®. Although the rate of reported suspected fatal bleeding associated with Pradaxa® as of 31 October 2011 is lower than the fatal bleeding incidence of 230 events per 100,000 patient years seen in the key pre-market clinical study evaluating the efficacy of Pradaxa®, RE-LY, these new recommendations have been issued to mitigate the risk of serious bleeding events arising from the use of Pradaxa® in patients with varying degrees of renal impairment.The recommendations include renal assessment through creatinine clearance calculation prior to initiation of Pradaxa® treatment, on-treatment renal assessment in cases of suspected renal function deterioration as well as annual on-treatment renal assessment for the elderly and patients with moderate renal impairment. The package insert of Pradaxa® will be updated with the relevant information.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg ↗ (opens in new tab) and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.